Drug development for neurodegenerative diseases is struggling with one of its most intractable barriers: the slow, variable, and subjective nature of clinical endpoints Traditional assessment scales, ...
A new review from the University of Cambridge explores ocular biomarkers in HD, including retinal scans and eye movement tracking.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results